SOURCE: Arcxis Biotechnologies

July 17, 2007 11:00 ET

Arcxis Biotechnologies Accelerates the BioPhalanx™ Analyzer With an Award From the U.S. Department of Homeland Security

Unique Portable Microarray Platform Will Rapidly Detect Bio-Threats

PLEASANTON, CA--(Marketwire - July 17, 2007) - Arcxis Biotechnologies ("Arcxis") announced today a Phase II award from the Department of Homeland Security, to continue development of the BioPhalanx™ Analyzer, a hand-portable instrument that is designed to rapidly detect bio-threats in the field. The $1,000,000 award follows the successful completion of Phase I, where a novel tentacle probe™ assay was demonstrated, providing DHS researchers with the first genomic assay that does not report false positive results for two important biological threat agents, Bacillus anthracis and Yersina pestis (the bio-threat agents for anthrax and plague respectively).

Phase II, which includes a "fast track" option, will help to fund product development by leveraging several technical advancements that are part of the Arcxis intellectual property portfolio. It will combine Arcxis micro preparation cards (MPC) for rapid sample preparation, Arcxis micro channel-based microarrays (MCM) for sensitive nucleic acid detection, and Arcxis tentacle probes™ for the design of several specific assays targeted at potential bio-threats.

"The BioPhalanx™ Analyzer represents a coming together of several unique technologies, which have been developed here at Arcxis, delivering speed, sensitivity and specificity," said Mr. Goldstein CEO, Arcxis. "As part of the development plan, Arcxis will deploy platforms and consumable devices at selected customer sites by end of year 2008," he added.

The BioPhalanx™ Analyzer is designed to be robust enough to be deployed in harsh environments and following the successful testing in the field, a decision will be made on the timing of the BioPhalanx™ Analyzer's unrestricted launch into the marketplace.

Arcxis Biotechnologies, headquartered in Pleasanton, California, is a private, venture-funded company that designs, develops and markets instrument systems and reagents for the isolation and purification of RNA and DNA. For additional information about Arcxis, please visit the company's website at www.arcxis.com.

Contact Information

  • Contact:
    J. Clark Mason, Ph.D.
    Director of Marketing
    Arcxis Biotechnologies
    6920 Koll Center Parkway, Suite 215
    Pleasanton, CA 94566
    Email Contact
    925 461 1300 (office)